**Review**

**Autonomic regulation of islet hormone secretion – Implications for health and disease**

B. Ahrén

Department of Medicine, Lund University, Malmö, Sweden

**Abstract**

The pancreatic islets are richly innervated by parasympathetic, sympathetic and sensory nerves. Several different neurotransmitters are stored within the terminals of these nerves, both the classical neurotransmitters, acetylcholine and noradrenaline, and several neuropeptides. The neuropeptides, vasoactive intestinal polypeptide, pituitary adenylate cyclase activating polypeptide and gastrin releasing peptide are constituents of the parasympathetic nerves, whereas the neuropeptides galanin and neuropeptide Y are localised to sympathetic nerve terminals. Furthermore, the neuropeptide calcitonin gene-related peptide is localised to sensory nerves and cholecystokinin is also an islet neuropeptide, although the nature of the cholecystokinin neuropeptide is not established. Stimulation of the autonomic nerves and treatment with neurotransmitters affect islet hormone secretion. Thus, insulin secretion is stimulated by parasympathetic nerves or their neurotransmitters and inhibited by sympathetic nerves or their neurotransmitters. The islet autonomic nerves seem to be of physiological importance in mediating the cephalic phase of insulin secretion, in synchronising the islets to function as a unit allowing oscillations of islet hormone secretion, and in optimising islet hormone secretion during metabolic stress, e.g. hypoglycaemia and neuroglycopenia. The autonomic nerves could also be involved in the islet adaptation to insulin resistance with possible implication for the development of glucose intolerance and Type II (non-insulin-dependent) diabetes mellitus. It is concluded that islet innervation, through the contribution of all branches of the autonomic nerves and several different neurotransmitters is of importance both for the physiology and pathophysiology of the islets. [Diabetologia (2000) 43: 393–410]

**Keywords** Islets, parasympathetic, sympathetic, acetylcholine, vasoactive intestinal polypeptide, pituitary adenylate cyclase activating polypeptide, gastrin releasing peptide, noradrenaline, galanin, neuropeptide Y, calcitonin gene-related polypeptide, cholecystokinin, insulin secretion, glucagon secretion, cephalic phase, oscillation, hypoglycaemia, impaired glucose tolerance, diabetes.
close proximity to all four major types of islet endocrine cells. Sometimes more than three nerve terminals were found to approach a single endocrine cell [3, 4]. The nature of these islet nerves was studied using histochemical and fluorescence staining techniques during the 1950s and 1960s. These techniques revealed localisation of cholinesterase to some of the islet nerves and catecholamines to other nerves, indicating that both cholinergic and adrenergic nerves innervate the islets [5, 6]. In general, the nerve fibres enter the islets along the vessels and form either a peri-insular network in the mantle zone of the islet or pass directly to an islet endocrine cell. During the 1960s, 1970s and 1980s, numerous functional studies showed changes in islet hormone secretion both after electrical activation of the autonomic nerves and by challenge with adrenergic and cholinergic agonists and antagonists in a variety of experimental conditions [2, 7, 8]. In the last two decades, it has also become apparent that apart from the classical neurotransmitters, several neuropeptides are also localised to islet nerve terminals. Because these neuropeptides also affect islet function, it has become apparent that neuropeptidergic nerves are involved in the neuroregulation of islet function as well [7, 9]. Figure 1 illustrates the neural relation to an islet with emphasis on the neurotransmitters involved. Finally, during recent years information has emerged suggesting islet autonomic nerves are involved in physiological and pathophysiological processes. In this article, our current knowledge of the role of autonomic regulation of islet function is reviewed, focusing on aspects of physiological and clinical importance.

Parasympathetic nerves

Anatomy. The cholinergic nerve fibres innervating the islets are of postganglionic origin and emanate from the intrapancreatic ganglia [7, 8]. These ganglia are controlled by the preganglionic fibres, originating primarily in the dorsal motor nucleus of the vagus [7, 8, 10]. The preganglionic fibres traverse the vagus, mainly as part of the bulbar outflow tract [8] and the hepatic and gastric branches of the vagus [10]. They enter the pancreas along the vessels and terminate at intrapancreatic ganglia, from which the postganglionic nerves pass to the islets; these nerves penetrate the islets to terminate close to the endocrine cells [7–9]. That parasympathetic nerves innervate the islets has been verified in a number of species by light and electron microscopy after staining pancreatic sections with cholinesterase [3, 5, 7, 8]. The relative abundance of the islet cholinergic innervation is evident because isolated islet tissue has a tenfold higher concentration of choline acetyltransferase than pancreatic tissue as a whole [11].

Effects. Already during the 1920s and 1930s it was hypothesised that vagal activation stimulates insulin secretion because electrical stimulation of the vagus nerve was found to lower blood glucose in both cats and dogs [2]. This hypothesis was verified after the introduction of radioimmunooassay techniques in the 1960s, when it became possible to measure islet hormones. Electrical activation of the vagus nerve was shown to stimulate insulin secretion both in vivo and in vitro in several different species including humans [7, 8, 10, 12–14]. Extrapancreatic stimulation of the
vagus nerve releases acetylcholine from the preganglionic terminals in the ganglia which activates nicotinic receptors on the nerve cell bodies of the postganglionic nerves. This implies a nicotinic mechanism mediates vagally induced insulin secretion. Verification came from findings that nicotinic blockade by hexamethonium abolishes the insulin secretory response to vagal nerve activation [14] and specific pharmacologic nicotinic activation in adrenalectomised animals (to exclude any action through a nicotinic-induced release of adrenaline) in vivo stimulates insulin secretion [15]. As has, however, been shown in the perfused canine pancreas, ganglionic transmission could be more complex than simply involving nicotinic mechanisms. Possibly several other transmission pathways are also involved [16], but this has not been explored in great detail.

The postganglionic nerve fibres innervating the islets release acetylcholine, which directly stimulates insulin secretion from the islet beta cells through activation of muscarinic receptors. The muscarinic nature of the action has been verified by immunocytochemistry showing localisation of muscarinic receptors in the islets with a higher density than in surrounding pancreatic tissue [17] and the detection of cDNAs encoding for muscarinic receptors in islet tissue [18]. Furthermore, numerous studies have found that exogenous treatment with acetylcholine or other muscarinic agonists stimulates insulin secretion in vivo and in vitro in several species by an effect which is inhibited by muscarinic antagonism by atropine [2, 7, 8, 19]. It has also been established that vagal nerve activation stimulates the secretion of the other three islet hormones, glucagon, somatostatin and pancreatic polypeptide (PP) [12, 13, 20]. The secretions of glucagon and somatostatin are likewise stimulated by pharmacological cholinergic agonism (acetylcholine or carbachol) [20–22]. It seems therefore to be established that the parasympathetic nervous system affects secretion of islet hormones by a general stimulatory action. The potent stimulation of PP secretion is of particular interest because the plasma concentration of PP is frequently used as an indirect marker for parasympathetic activity [23].

**Islet muscarinic receptor subtype.** At present five different muscarinic receptors (m receptors) have been discovered with subtype specific characteristics for gene encoding, cellular expression and signalling mechanisms [24]. Several pharmacological studies have been undertaken to establish which muscarinic receptor subtype is important for insulin secretion. An m3 receptor antagonist was found to inhibit cholinergically induced insulin secretion and bind more efficiently to isolated rat islets than m1 or m2 receptor antagonists [25]. Furthermore, in isolated mouse islets, antagonists to m1 and m2 receptors have no effect on cholinergically induced insulin secretion [26]. Moreover, in vivo in mice, m3 receptor antagonist inhibits cholinergically induced islet hormone secretion more efficiently than inhibitors of the m1 and m2 receptor subtypes [22]. Glucagon secretion, like insulin secretion, is also stimulated by activation of the m3 receptor subtype [22, 25]. Therefore, the indications so far are that the m3 receptor subtype is important for mediating cholinergically induced islet hormone secretion. This is also supported by cDNAs encoding for m3 receptors in islets [18].

**Islet signalling of muscarinic receptor activation.** A main characteristic of cholinergic islet effects is a synergistic action with glucose to augment both insulin secretion and phosphoinositide (PI) hydrolysis [27] (Fig. 2). Phosphoinositides hydrolysis is stimulated by phospholipase C (PLC) by a mechanism coupled to G-protein. This coupling is initiated by an agonist binding the muscarinic receptors [28]. Hydrolysis of PI results in formation of IP3, releasing Ca2+ from intracellular Ca2+ stores to raise the cytosolic concentration of Ca2+. Consequently, cholinergic agonism increases the cytosolic concentration of Ca2+ independently from uptake of extracellular Ca2+, which is accompanied by a rapid stimulation of exocytosis and insulin secretion [19, 25, 29]. Because cholinergic agonism activates PLC, diacyl glycerol (DAG) is also formed [30] and because DAG activates protein kinase C (PKC), insulin secretion induced by carbachol has been shown to be reduced by inhibition of PKC [31]. Moreover, cholinergic agonism also stimulates the generation of arachidonic acid (AA) through activation of PLA2 [32, 33]. Carbachol has been shown to be even more efficient than glucose in activating PLA2 [32]. The effect activation of PLA2 has on insulin secretion, induced by cholinergic agonism, is evident from findings that a PLA2 antagonist greatly inhibits exocytosis stimulated by acetylcholine in insulin producing cells [32]. In contrast, carbachol does not seem to increase islet formation of cAMP [19]. The combined action of cholinergic agonists (to release Ca2+ from intracellular stores, to raise the cytosolic concentration of Ca2+, to stimulate the formation of AA and to activate PKC) seems to contribute to the inotropic action after activation of the muscarinic receptors. In contrast, the signalling underlying cholinergically induced glucagon secretion is still to be established.

**Non-cholinergic mechanisms.** Several studies have shown that vagally induced islet hormone secretion is not always sensitive to inhibition by muscarinic antagonism by atropine. In the pig pancreas, for example, vagally induced insulin secretion is resistant to atropine although it is inhibited by hexamethonium [13]. Similarly, in the dog, vagally induced glucagon secretion is resistant to atropine, although atropine reduces more than 80% of vagally induced insulin se-
cretion in this species [14]. Furthermore, vagally induced somatostatin and PP secretion from the dog pancreas is only partially prevented by atropine [20]. Therefore, although pharmacological cholinergic agonism clearly can stimulate islet hormone secretion through a muscarinic mechanism, non-cholinergic mechanisms also seem to contribute to the action of parasympathetic nerves. This has prompted the search for the non-cholinergic and presumably peptidergic signal(s) which, together with acetylcholine, are responsible for the potent islet hormone secretory response to vagal activation.

**Parasympathetic islet neuropeptides.** Immunocytochemistry has revealed three neuropeptides in nerve terminals in pancreatic ganglia and in islets in several different species: vasoactive intestinal polypeptide (VIP), gastrin releasing peptide (GRP) and pituitary adenylate cyclase activating polypeptide (PACAP) [7, 9, 34–37]. These neuropeptides are released from the pancreas on electrical vagal activation [35, 36, 38]. Furthermore, these neuropeptides stimulate both insulin and glucagon secretion in vivo as well as in vitro [35–44]. Both from a morphological and functional point of view, they are therefore candidates for contributors to islet hormone secretion induced by vagal nerve activation.

Vasoactive intestinal polypeptide and PACAP are ubiquitously distributed neuropeptides with close structural resemblances; VIP consists of a 28 amino acid residue whereas PACAP exists in two forms consisting of 27 and 38 amino acids and they show 68% identity [45]. The close relation between these two neuropeptides is further evident from the finding that the two cloned receptor subtypes with affinity for VIP both also have an affinity for PACAP (VIP₁ and VIP₂ receptors, [45]). In addition, there exists a third receptor specific for PACAP (called PAC₁ re-
Summary. There are four different neurotransmitters localised to islet parasympathetic nerves (acetylcholine, VIP, PACAP and GRP), all of which are released by activation of the vagus nerve and all of which stimulate insulin and glucagon secretion. They could therefore all contribute to vagally induced stimulation of insulin and glucagon secretion. The four potential parasympathetic neurotransmitters activate islet signalling mechanisms which are partially different. The relative contribution of the four neurotransmitters to the islet hormone responses to vagal nerve activation is not known and needs to be established.

Sympathetic nerves

Anatomy. The first finding of a potential islet role of the sympathetic nerves was presented in 1940 when it was found that sympathetic nerve activation is accompanied by microscopical changes in the islets [2]. An extensive adrenergic innervation of the islets was later shown by fluorescence microscopy. A rich supply of nerve endings containing amine in close connection with the islet endocrine cells was made visible in several species [6]. Furthermore, islet innervation of adrenergic nerves has also been supported by the localisation in islets of labelled noradrenaline or 5-hydroxytryptophan from intact animals that had been given these neurotransmitters in vivo [3]. Moreover, by electron microscopic studies adrenergic nerve terminals in close association with islet endocrine cells have been made visible [54]. Finally, immunocytochemistry has revealed an extensive innervation of islets by staining of islet nerve terminals with enzyme catalysing the formation of noradrenaline, tyrosine hydroxylase [54–56]. The adrenergic nerves innervating the islets are postganglionic with most nerve cell bodies located in the celiac ganglion or in the paravertebral sympathetic ganglia [7, 8]. The preganglionic nerve fibres originate from nerve cell bodies in the hypothalamus and leave the spinal cord at the level of C8 to L3. The fibres then traverse the lesser and greater splanchnic nerves to reach the paravertebral or celiac ganglia [8]. The preganglionic fibres pass from the ganglia within the mixed autonomic nerves which enter the pancreas along its vessels but preganglionic sympathetic nerve fibres can also directly enter the pancreas.

Effects. Electrical activation either of the splanchnic nerves or of the mixed autonomic nerves along a pancreatic artery can be used to examine islet hormone secretion after sympathetic nerve activation. A drawback of the first approach is that other tissues innervated by these nerves are also stimulated allowing indirect influences. The second experimental approach is therefore more specific for activation of the pancreas. For a specific sympathetic activation, this approach requires, however, a concomitant blockade of the joint preganglionic cholinergic nerves. This has usually been accomplished by ganglionic blockade by hexamethonium or muscarinic antagonism by atropine. The result of such stimulation is inhibition of basal and glucose-stimulated insulin secretion as evident both in dogs and calves [57, 58]. Electrical activation of the sympathetic nerves attached to an isolated pancreas preparation also results in inhibition of glucose-stimulated insulin secretion in rats [59], pigs [60] and humans [8]. Electrical activation of the sympathetic nerves further induces a large release of noradrenaline into the pancreatic veins [58]. Because exogenous treatment with noradrenaline inhibits glu-
cose-stimulated insulin secretion [61], it has been assumed that it is noradrenaline which mediates the inhibitory action of electrical sympathetic activation on glucose-stimulated insulin secretion. This is supported by studies showing that α-adrenoceptor blockade by phentolamine counteracts the inhibition of glucose-stimulated insulin secretion by electrical nerve activation [57, 59] and that a specific α2-adrenoceptor agonist, clonidine, inhibits glucose-stimulated insulin secretion [62]. Noradrenaline could, however, also stimulate insulin secretion by two different actions. Firstly, through its activation of the islet β2-adrenoceptors which stimulates insulin secretion [63]. Secondly, through a direct action on the alpha cells, probably mediated by both α2-adrenoceptors and β2-adrenoceptors, which stimulate glucagon secretion [64, 65]; glucagon might in turn stimulate insulin secretion. Therefore, the net effect of noradrenaline on insulin secretion might depend on the relative abundance or activity of α-adrenoceptors compared with β-adrenoceptors on the beta cells, which might differ under different conditions and on the action through glucagon. It should be emphasised that several types of α2-adrenoceptors have been expressed in islets and these have been localised to either alpha or beta cells [66, 67]. Furthermore, α2-adrenoceptor activation might increase the local noradrenaline concentration in close vicinity to the beta cells, due to a presynaptic inhibition of noradrenaline uptake [68]. Several direct and indirect mechanisms could, therefore, contribute to the effects of noradrenaline on insulin secretion. In studies using α-adrenoceptor blockade as a tool this could be a problem in interpretation because local increase in noradrenaline in combination with postsynaptic α2-adrenoceptor blockade could lead to a net stimulation of insulin secretion by β-adrenoceptor activation. This could offset any inhibition by other mediators. Therefore, approaches using noradrenaline to mimic endogenously released noradrenaline or using a combined α-adrenoceptor and β-adrenoceptor blockade are required to establish the contribution by noradrenaline to the effects of sympathetic nerve stimulation. It has thereby been established that under conditions of stimulated insulin secretion noradrenaline potently inhibits insulin secretion and therefore probably mediates this action of the sympathetic nerves [61, 69]. In contrast, this does not, however, seem to be the case for basal insulin secretion because although sympathetic nerve stimulation clearly inhibits basal insulin secretion, a local infusion of noradrenaline into the pancreatic artery over a wide dose range increased, not reduced, insulin secretion in the dog [58]. Furthermore, combined α2-adrenoceptor and β-adrenoceptor blockade by yohimbine and propranolol could not counteract the inhibition of basal insulin secretion induced by electrical sympathetic activation in dogs, yet the combined adrenergic blockade inhibited the effects of exogenously added noradrenaline [70]. Therefore, noradrenaline does not seem to mediate inhibition by sympathetic nerve stimulation of basal insulin secretion, which therefore might be peptidergic.

The sympathetic nerves also regulate the secretion of the other islet hormones. Thus, glucagon and PP secretions are stimulated by sympathetic nerve activation [57–60, 70, 71] whereas somatostatin secretion is inhibited [71, 72]. The mechanism of the changes in the secretion of the other islet hormones after sympathetic nerve stimulation is less well characterised. Most studies suggest, however, that these effects are mediated by both α2-adrenoceptors and β2-adrenoceptors as well as by non-adrenergic mechanisms [57–60, 64, 65, 70–72].

Islet signalling of adrenoceptors. Glucose-stimulated insulin secretion is inhibited by noradrenaline activating the α2-adrenoceptors or direct activation of these receptors by, for example, clonidine. This inhibition has been shown to be mediated by hyperpolarisation of the beta cells through opening of the ATP-regulated K+ channels thereby inhibiting the Ca2+ uptake and reducing the cytoplasmic concentration of Ca2+ [73]. Therefore, reduction of the cytoplasmic concentration of Ca2+ is a signalling hallmark of the action of noradrenaline. Activation of islets by α2-adrenoceptor has, however, also been shown to inhibit insulin secretion through reduced formation of cyclic AMP [74] and through an inhibitory action on the distal exocytotic machinery [75]. Therefore, several signalling mechanisms seem to underlie the insulinostatic action of noradrenaline. The stimulatory action of β-adrenoceptor is mediated by increased formation of cAMP in the beta cells [76].

Non-adrenergic mechanisms. The non-adrenergic contribution to the inhibitory action of sympathetic nerves on insulin secretion is possibly mediated by galanin or neuropeptide Y (NPY) or both. These neuropeptides are both localised to the islet sympathetic nerve terminals. This is evident from several different species in which they are co-localised to the adrenergic marker, tyrosine hydroxylase or greatly depleted by 6-hydroxy-dopamine which selectively destroys the sympathetic nerve terminals [56, 77, 78]. Galanin and NPY are also localised to nerve cell bodies in the celiac ganglion, as shown in dogs [56]. Furthermore, galanin is released from the pancreas upon electrical activation of the sympathetic nerves [77] and galanin and NPY both inhibit insulin secretion, in vivo and in vitro [77–81]. The involvement of galanin in inhibition of insulin secretion induced by activation of sympathetic nerves is particularly important in dogs, where galanin is released into the venous effluent of the pancreas during pancreatic sympathetic stimulation in a quantity which is sufficient.
to inhibit insulin secretion [82]. Furthermore, in mice immunoneutralisation of galanin partially prevents a reduction of glucose-stimulated insulin secretion by exercise stress, which is mediated by sympathetic nerve activation [83]. The problem with the concept of a possible contribution by galanin and NPY to sympathetically induced changes in islet hormone secretion is that there seems to be a profound difference between species in the islet localisation and effects of the two neuropeptides. Whereas, for example, dog islets have an extensive galanin innervation, there is only a scanty innervation by galanin nerves in rat or human islets [78]. In mice and pigs, NPY seems to be a constituent not only of sympathetic nerve terminals but also of parasympathetic nerve terminals [55, 84]. Although a potent inhibition by galanin of insulin secretion has been reported in vivo in dogs [77] no such effect is evident in humans [85]. Inhibition by NPY of glucose-stimulated insulin secretion has been found in studies on rodents [55, 79–81] but no clear effect in dogs [86]. In the pig, galanin and NPY have both been shown to stimulate, not inhibit, insulin secretion [84, 87]. All these findings could be explained, by different experimental conditions, by expression of different receptors under different conditions. Convincing evidence indicating that galanin or NPY contributes to sympathetically induced inhibition of insulin secretion has therefore been presented in only a few species. In future, studies with new approaches on the potential involvement of galanin and NPY in neural regulation of islet function are required. One such approach would be the use of specific receptor antagonists. These receptor antagonists have not been systematically examined after activation of the sympathetic nerves except in a few studies using isolated rat islets or insulin-producing cells which have shown that the galanin receptor antagonist galantide [88] or the NPY receptor antagonist (R)-N-(2)-(diphenylacetyl)-N’-[4-hydroxyphenyl]methyI]argininamide (BIBP) 3226 [81], prevents galanin or NPY, respectively, from inhibiting insulin secretion. Another approach is the use of mice that have been made deficient of galanin, NPY or their receptors by disruption of the genes. Although galanin-deficient and NPY-deficient mice are available, they have not yet been examined in detail in this respect. Therefore, the net contribution of these neuropeptides to the sympathetic regulation of islet function is not yet established.

**Cellular NPY.** It should also be mentioned that under some conditions of insulin resistance, such as dexamethasone treatment of rats, NPY is also expressed in islet endocrine cells and that immunoneutralisation of NPY in islets isolated from such rats results in augmentation of insulin secretion [89]. This implies there is a compensatory or adaptive islet mechanism in insulin resistance involving local islet expression of NPY. This mechanism and function of the neuropeptide would be distinct from its potential role as an islet sympathetic neurotransmitter. A relation between these roles is, however, possible in view of recent findings that chemical sympathectomy by means of 6-hydroxydopamine prevents the expression of NPY in islet endocrine cells after dexamethasone-induced insulin resistance in rats [90]. This implies that the sympathetic nerves regulate the beta-cell expression of NPY. The relevance of this influence in relation to insulin secretion is still to be established.

**Islet signalling by galanin and NPY.** Both galanin and NPY activate several different receptor subtypes for inducing biological responses. Three galanin receptors (GalR1, GalR2 and GalR3) have been cloned [91] and one of them, GalR1, is expressed in insulin-producing cells [92]. The powerful inhibitory influence of galanin in rodent islets has been shown to be accompanied by a complex signalling mechanism, involving hyperpolarisation and reduction in the cytosolic concentration of Ca2+, although reduced formation of cAMP and inhibition of a direct exocytotic mechanism could also contribute [78]. At least six different NPY receptors have been cloned (Y1, Y2, Y3, Y4, Y5 and Y6 receptors), some of which share an affinity with peptide YY (PYY) and PP [93, 94]. In insulin-producing cells, most evidence favours the Y1 receptor subtype as the receptor mediating islet actions of NPY [81]. The mechanism underlying the inhibition by NPY of glucose-stimulated insulin secretion is not fully established. It seems to involve inhibition of adenylate cyclase with reduced formation of cAMP [81] as well as distal mechanisms in relation to formation of cAMP because insulin secretion stimulated by a cAMP analogue is also inhibited by NPY [80].

**Summary.** Sympathetic nerves innervate the islets and three neurotransmitter candidates are localised to these nerves and released on their activation (noradrenaline, galanin and NPY). Activation of the sympathetic nerves inhibits basal and glucose-stimulated insulin secretion. Although mediation of this effect by noradrenaline has been established, mediation of the inhibited basal insulin secretion is still not established. Furthermore, the relative contribution of galanin and NPY to islet effects of the sympathetic nerves is also still to be established.

**Sensory nerves**

Apart from being innervated by cholinergic and adrenergic nerves, each individual islet is also extensively innervated by a network of sensory nerves with nerve terminals harbouring the sensory neuropeptides, calcitonin gene-related peptide (CGRP)
and substance P (SP). The localisation of the 37-amino acid peptide CGRP to islet nerves was first reported in 1983 [95]. Nerves harbouring the 11-amino acid peptide SP, although less numerous than CGRP nerves, have also been found in the pancreatic islets [96]. These sensory islet nerves have been shown to innervate mainly the peripheral portions of the islets [95, 96] although occasional nerve fibres are also found in the central part [96]. The fibres are thought to leave the pancreas along the sympathetic fibres within the splanchnic nerves to reach the spinal cord [8]. The role of the islet sensory nerves is far from understood. During recent years results have, however, been presented indicating that the nerves could be involved in the regulation of islet hormone secretion and glucose homeostasis. One line of evidence for such a conclusion is that both CGRP and SP affect islet hormone secretion. Thus, CGRP has been shown to inhibit insulin secretion through a direct action on the islets [97–99] which is accompanied by reduction in cAMP through a pertussis sensitive mechanism [99]. The CGRP receptor subtype responsible for its inhibition of insulin secretion has not yet been established. It should be mentioned that CGRP is related to islet amyloid polypeptide (IAPP). This is a beta-cell peptide of interest in islet physiology because apart from its potential role in diabetes pathophysiology by forming amyloid fibrils, it has the potential to inhibit insulin secretion [100]. Furthermore, there is a relation in receptor affinity between CGRP and IAPP and also other members of this family of peptides (i.e., calcitonin and adrenomedullin). It has been shown that the so-called “receptor activity-modifying proteins” (RAMP1, RAMP2 and RAMP3), which are single transmembrane proteins modulating the affinity of receptors, transport the calcitonin receptor-like receptor (CRLR) to the cell surface. Depending on which RAMP is transporting the receptor to the surface, affinity for either CGRP, IAPP, calcitonin or adrenomedullin evolves. It has thus been proposed that it is the RAMP1-transported CRLR which results in a receptor form with high affinity for CGRP [101, 102]. Similar regulation has been proposed for the calcitonin receptor [103]. These newly discovered receptor regulatory mechanisms might be of relevance for the function of these peptides [101]. Whether such a mechanism is operative in islet beta cells is still, however, to be established. In contrast to the inhibition by CGRP that has been shown, the influence of SP on insulin secretion is less well characterised. Both inhibitory [104] and stimulatory [105] effects have been reported.

The possible role of the sensory nerves in the regulation of islet function and glucose homeostasis has also been examined with the use of the drug capsaicin as a tool. Treatment of rodents with this agent results in de-afferentation of small unmyelinated C-fibres with a concomitant large reduction in tissue content of CGRP [106]. A substantial reduction of CGRP immunoreactive nerves and a partial reduction in SP immunoreactive nerves has also been shown in islets from mice treated with capsaicin when newborn [96]. This results in an increased glucose-stimulated insulin secretion in the intact mouse [107], suggesting that sensory nerves through their inhibitory neuropeptide CGRP exert a tonic inhibition of insulin secretion. The result in vivo of potentiated glucose-stimulated insulin secretion in mice treated with capsaicin could also indicate that the sensory nerves are involved in a neural reflex activated by glucose, perhaps through activation of glucose sensors in the portal area [108]. Such a reflex could involve efferent adrenergic nerves, judging from studies showing that α-adrenoceptor blockade is unable to increase circulating insulin after capsaicin treatment in mice [107]. This would suggest that sensory nerves affect islet function by two mechanisms: by providing a local neural effector function in islets and by being involved in a neural circuit involving peripheral adrenergic nerves.

It has also been shown that glucose elimination is increased in mice after capsaicin treatment [107]. This could be explained as a consequence of the potentiated insulin secretion but also by an increased insulin action because a similar increased elimination was found in streptozotocin diabetic rats [109]. The glucose disposal during recent euglycaemic, hyperinsulinaemic clamp studies was also increased in capsaicin-treated rats [110]. These results imply that the peripheral action of insulin is likewise dependent on intact sensory nerves, which is supported by in vitro studies showing that CGRP reduces the action of insulin [111]. The functional implication and possible relation to Type II diabetes of the potentiation of insulin secretion and improvement of insulin action after capsaicin treatment deserves to be studied in greater detail.

Sensory nerves could also be involved in the regulation of glucagon secretion. Thus, treatment with CGRP stimulates glucagon secretion [98] and the glucagon response to neuroglycopenia induced by the glucose analogue, 2-deoxy-glucose (2-DG), is inhibited after capsaicin treatment [96]. This would suggest that although the sensory nerves inhibit insulin secretion, they stimulate glucagon secretion. Notably, a previous study showed that glucose recovery from insulin-induced hypoglycaemia was impaired after capsaicin treatment [112]. This could imply the regulation of glucagon secretion by the sensory nerves during hypoglycaemia is of physiological importance.

Other nerves

During recent years, nerve fibres not strictly related to the sympathetic, parasympathetic or sensory nervous system have also been found in the endocrine
pancreas, e.g. nerve fibres stained for a marker of nitric oxide synthase in islets [113]. This suggests that nitric oxide nerves participate in the regulation of islet function, which is supported by the finding that inhibition of nitric oxide synthase inhibits insulin secretion induced by 2-DG in mice [114]. Furthermore, cholecystokinin is also localised to islet nerves [115]. The CCK nerves might be of importance for insulin secretion because CCK is a potent stimulator of insulin secretion through activation of CCK-A receptors; the insulinotropic activation of CCK is mediated by PLC and PLA2 [33, 116]. Finally, it has been shown that nerves originating in ganglia in the duodenum might pass directly to the pancreas and innervate pancreatic ganglia, suggesting the existence of a direct entero-pancreatic neural mechanism [117]. The role of these “other” nerves in the regulation of islet function and their relation to the influence of the three main branches should certainly be explored in the future.

Islet autonomic nerves and cephalic phase regulation of islet hormone secretion

Cephalic phase of insulin secretion. Autonomic and endocrine responses to food ingestion which are triggered by sensory mechanisms and not by the absorbed nutrients are called cephalic phase responses. They consist of three different pathways: first the afferent pathway activated by olfactory, visual, gustatory and oroparyngeal mechanical receptors, second the central integratory mechanism and third the efferent pathway [118]. In rats, a cephalic phase regulation of insulin secretion has been verified by insulin secretion seen during sham feeding [119, 120], after food ingestion but before any significant increase in postabsorptive glycaemia is evident [121, 122], and after ingestion of non-metabolisable food [123]. In humans, a cephalic phase regulating insulin secretion was first shown by an increased circulating insulin after imaginary food ingestion under hypnosis [124] and after the sight, smell and expectation of food in healthy subjects [125]. Also combined taste-feeding and ingestion of non-metabolisable sweetener [126] and sham feeding [127] was found to elicit rapid and reliable insulin responses in normal subjects. Moreover, a rapid increase in circulating insulin after oral glucose, before any increase in circulating glucose, has been shown in normal subjects [128]. The cephalic response of insulin secretion is seen in humans within the first 3–4 min, and therefore, when studying this response it is important to sample at an early time after initiation of the stimulus [127].

The cephalic phase stimulation of insulin secretion is activated through stimulation of oral taste receptors and the central integrative circuit has been localised to the ventro-medial hypothalamus and to the dorsal motor nucleus of the vagus [10, 119]. The effector pathway is mediated by the cholinergic neurons within the vagus nerves because it is abolished by vagotomy, by ganglionic blockade and by muscarinic antagonism [119, 121, 122]. Whether the neu-

---

**Fig. 3 A, B.** Serum insulin (A) and plasma glucose (B) before and at different time points after ingestion of a standard breakfast consisting of two slices of bread, 10 g margarine, 10 g marmalade, a slice of 15% cheese and a cup of black coffee (350 kcal with 28, 22 and 50% of energy coming from protein, fat and carbohydrate, respectively) in six healthy postmenopausal women, 63 years of age. Either saline or the ganglionic antagonist, trimetophane (0.3 to 0.45 mg · kg⁻¹ · min⁻¹) was infused intravenously from min –10 to min 15. Insert is the area under the suprabasal insulin as calculated by the trapezoid rule for min 0–15 after start of meal ingestion during infusion of saline (S), trimetophane (T) or during a third experimental condition, when atropine (A) was given as a bolus injection of 0.5 mg at min –10, followed by an intravenous infusion at a rate of 0.05 mg · kg⁻¹ · min⁻¹ until min 15 (results of this experimental series or its saline control not shown as insulin or glucose data). Means ± SEM are shown. Asterisks indicate the probability level of random difference compared with the control series when saline was infused as determined by a paired non-parametric Wilcoxon signed rank test; *p < 0.05, **p < 0.01. ———, Saline; ———, trimetophane.
ropeptides in the parasympathetic nerves (VIP, PACAP, GRP) contribute to the cephalic phase regulation of islet function is not known. We recently did a series of experiments to examine this by infusing the ganglionic antagonist, trimetophane or the muscarinic antagonist, atropine, into six healthy subjects during ingestion of a meal. In the control experiments, when saline was infused together with the meal intake, there was a clear early insulin response, with insulin concentrations being increased within the first few minutes after meal intake (Fig. 3). When trimetophane was infused, this early insulin response was, however, almost completely abolished and infusion of atropine inhibited the early (15-min) response by approximately 30% (Fig. 3). This supports the hypothesis that humans also have a cephalic phase regulating insulin secretion and suggests that it is mediated by a ganglionic mechanism and that the postganglionic mechanism is both cholinergic and non-cholinergic. In a recent experimental study in mice a selective PACAP receptor antagonist reduced the early insulin response to a gastric glucose gavage [129]. Although this is not equivalent to the cephalic phase of insulin secretion it suggests involvement of a peptidergic mechanism in the early insulin response to food intake.

Relevance of early insulin response for glucose tolerance. The contribution by the cephalic phase to the entire postprandial insulin secretion is in the range of only 1–3% of the total insulin secretion after intake of a meal [130]. In spite of this small contribution, the cephalic phase has been suggested to be of considerable functional importance for the rate of glucose excursion and therefore glucose tolerance after meal intake. Thus, rats with transplanted islets, presumed to be denervated, were glucose intolerant after being given administration orally [131]. Treating denervated rats with a minute amount of insulin, to mimic the insulin profile which is seen immediately after oral glucose in normal rats restores glucose tolerance [119]. When glucose is supplied to the gastrointestinal tract but bypassing the oral cavity in the rat (which excludes a cephalic phase of insulin secretion) glucose intolerance is seen [132]. Several studies in humans have also reached similar conclusions. One study for example has shown that the degree of insulin secretion during the cephalic phase correlates negatively to the rise in circulating glucose and positively to the glucose metabolism during a hyperglycaemic clamp [133]. Another study has shown that a simultaneous taste of food in combination with intragastric treatment with glucose increases glucose tolerance [130]. Inhibition of the early prandial insulin response by somatostatin results in deterioration of glucose tolerance [134] and inhibition of the early (15-min) response to a meal by the ganglionic antagonist, trimetophane, is accompanied by increased glucose concentrations at min 45 and 60 (Fig. 3). Finally, a brief treatment with insulin during the first 15 min after food ingestion considerably improves glucose tolerance in subjects with Type II diabetes [135]. Therefore, the cephalic phase regulation of insulin secretion, albeit being marginal in the relation to the entire prandial insulin secretion, seems to be of utmost importance for preserving a normal glucose tolerance after oral glucose. Because the cephalic phase of insulin secretion is mainly neural, these findings indicate that the autonomic nerves have an important role in the preservation of normal glucose tolerance after a meal.

Cephalic phase and glucagon secretion. Apart from a cephalic phase regulation of insulin secretion, a cephalic phase regulation of glucagon secretion has also been shown in rats [136], dogs [137] and humans [130]. The importance of cephalic phase regulation of glucagon secretion is still, however, to be studied in more detail.

Islet autonomic nerves and the synchronisation of islet function

It is known that individual islet beta cells secrete insulin in a pulsatile manner and that cellular metabolism also shows oscillatory patterns as seen for oxygen consumption, production of ATP and concentrations of cytosolic Ca$^{2+}$ [52, 138, 139]. This suggests that each cell is a pacemaker for oscillatory regulation of metabolism and secretion. Islet function is also regulated in an oscillatory manner, suggesting islet cells are synchronised so that the islet works as a functional unit. This islet synchronisation has been shown to be due to multiple mechanisms [140]. Insulin secretion from the entire pancreas, not only from individual islets, has also, however, a regular pulsatility [141]. It is therefore likely that synchronisation between islets occurs as well. Recent studies suggest that it is the pancreatic ganglia that governs this synchronisation. Thus, electrophysiological studies have shown that the pancreatic ganglia oscillates [142] and that inhibition of this neuronal activity in the perfused pancreas by nicotinic blockers [143] or by tetrodotoxin [144] abolished the oscillation in insulin secretion. Furthermore, after islet transplantation, the oscillation in insulin secretion disappears but the co-ordinated pattern of insulin release returns when the graft is reinnervated [145]. The autonomic nerves, perhaps governed by the intrapancreatic ganglia, seem therefore to synchronise the islets. This is probably of great clinical importance because both impaired glucose tolerance and Type II diabetes are characterised by disturbed oscillatory patterns [141]. When the oscillatory pattern is lost, however, in for example diabetes, it is not known whether this is a primary neural dys-
function or reflects a primary islet dysfunction. One study has shown that when the oscillatory pattern of circulating insulin is lost in the portal vein, liver extraction of insulin is altered, suggesting that the pulsatile pattern of insulin secretion is important for liver insulin extraction and therefore for systemic insulin infusion in subjects with Type I (insulin-dependent) diabetes mellitus, further supporting a physiological role of the pulsatile pattern of insulin secretion [147]. In contrast, in isolated perfused rat livers, insulin seemed equipotent in suppressing the glucose outflow whether given continuously or in a pulsatile fashion [148].

**Islet autonomic nerves and homeostatic mechanisms**

**Glycopenic stress.** During glycopenic stresses such as hypoglycaemia or neuroglycopenia, glucagon secretion is stimulated considerably whereas insulin secretion is inhibited, providing a mechanism for the recovery of circulating glucose through stimulation of hepatic glucose output and inhibition of peripheral glucose uptake [23]. Protection against hypoglycaemia is also achieved by other mechanisms, e.g. release of adrenaline and cortisol as well as a direct stimulation of the release of glucose from the liver [149]. Several studies have shown that the islet nerves are activated during glycopenic stress, thus providing a basis for neural contribution to the changes in islet hormone secretion [23]. Pancreatic polypeptide (marker for parasympathetic nerves) and noradrenaline (marker for sympathetic nerves) were, for example, released into the pancreatic vein during hypoglycaemia in conscious dogs [150]. Neuropeptides localised to the islet autonomic nerve terminals are released during endogenous activation of the autonomic nerves by glycopenic stress (e.g. galanin [151] and VIP [152]), indicating that islet neuropeptidergic fibres are also activated by glycopenic stress. These results imply that local islet nerves are involved in physiological islet adaptation to these metabolic stresses and both the classical neurotransmitters and the neuropeptides mediate the responses. More studies have suggested that this activation of the autonomic nervous system indeed contributes to the islet responses to these metabolic stresses. Ganglionic blockade by hexamethonium, which prevents the autonomic activation during glycopenic stress, considerably reduces for example the glucagon response to hypoglycaemia as well as to neuroglycopenia induced by 2-DG [151, 153]. It was recently also found that in healthy humans ganglionic blockade by trimetaphane prevents hypoglycaemia-induced glucagon secretion by approximately 75%, supporting a major role for the autonomic nerves in the mediation of glucagon secretion during glycopenic stress in humans [154]. This was confirmed in a case report in which a disease process, that disrupted the activation of the autonomic nerves because of a sarcoid infiltration in the hypothalamus, was associated with an impaired glucagon response to hypoglycaemia [155]. Atropine and adrenergic blockade have also been shown to inhibit glycopenia-induced glucagon secretion, further indicating its neurogenic nature [156]. Therefore, the islet nerves seem important for the mediation of glucagon secretion during glycopenic stress. The relative contribution of parasympathetic compared with sympathetic mechanisms as well as between classical neurotransmitters and neuropeptides is however, still to be established. This neural mediation of the glucagon response to hypoglycaemia seems to have great importance for glucose counterregulation, as is evident from the human study in which the impaired glucagon response during ganglionic blockade correlated to the amount of glucose infused to retain the desired hypoglycaemic value [154].

The contribution by the autonomic nerves to the islet response to hypoglycaemia has clinical implications in view of the impaired glucagon response to hypoglycaemia which is often seen in Type I diabetes [152, 157, 158]. Autonomic failure could therefore contribute to this impairment and because such failure could be induced by previous hypoglycaemia [159], avoidance of hypoglycaemia is of importance. Therefore, although autonomic failure has not been convincingly shown to be a major cause of impaired glucagon response to hypoglycaemia in Type I diabetes, substantial evidence exists that autonomic nerves are of major importance for the glucagon response to glycopenia in healthy humans and in experimental animals.

**Exercise stress.** Carbohydrates are the predominant fuel during exercise. In early exercise, breakdown of muscle glycogen serves as the main fuel but as exercise continues glucose delivery from the liver becomes more important [160]. Increasing hepatic glucose delivery is achieved by increased glucagon and lowered insulin concentrations [161–163] although direct activation of hepatic glycogenolysis by liver nerves contribute [163]. A model of standardised swimming stress in mice has been developed to explore the mechanism of the changes in islet hormone secretion during exercise. The model includes 2 min of swimming, which results in a 50% reduction in glucose-stimulated insulin secretion concomitantly with a 50% increase in circulating glucagon [164]. These changes are partially prevented by ganglionic blockade, by α-adrenoceptor antagonism and by sympathetic denervation by 6-hydroxydopamine. This indicates they are mediated by activation of the sympathetic nerves through adrenergic mechanisms [165, 166]; sympathetic nerve activation inhibits insulin
and stimulates glucagon secretion (see above). Mice were pretreated with a high-titre galanin antiserum to examine whether the remaining part of the inhibition of glucose-stimulated insulin secretion during swimming stress is mediated by sympathetic neuropeptides. The rationale for the experiment was the hypothesis that if galanin is a functionally important sympathetic neurotransmitter, immunoneutralisation of the peptide would impair the stress-induced inhibition of insulin secretion. This was also the result because the galanin antiserum was found to prevent the inhibition of insulin secretion during the swimming stress [83]. It is likely, therefore, that the sympathetic nerves make a major contribution to the changes in islet hormone secretion during exercise and this is, at least in experimental animals, mediated in part by noradrenaline and in part by galanin, both released from the islet sympathetic nerve terminals. Adrenaline released from the adrenals seems also to contribute to the changes in islet hormone secretion during exercise under these conditions because like 6-hydroxydopamine, adrenalectomy prevents the inhibition of insulin secretion and stimulation of glucagon secretion in mice while swimming [165]. The combined action of the adrenals and the sympathetic nerves could also be explained by a sequential action. Thus it has been shown in swimming rats that adrenaline released from the adrenals stimulates the local release of noradrenaline from the islet nerve terminals through a β₁-adrenoceptor-mediated action [166]. Noradrenaline might therefore be released both by direct sympathetic activation and indirectly by a presynaptic inhibition of re-uptake induced by adrenaline. Adrenaline might inhibit insulin secretion both by a direct islet action and indirectly by stimulating the liberation of noradrenaline from local islet nerve terminals. This is supported by a study in which the inhibitory influence of adrenaline on glucose-stimulated insulin secretion was partially prevented by destruction of local islet nerve terminals by 6-hydroxydopamine in isolated mouse islets [167]. The relative contribution of the adrenals and that of the local islet nerves to the changes in islet hormone secretion during exercise is difficult to establish. A major contribution by the sympathetic nerves to changes in islet hormone secretion during exercise is also evident in humans because inhibition of insulin secretion occurs in adrenalectomised humans during exercise by ergometer cycling [168].

Hypovolaemic stress. It is known that insulin secretion is inhibited and glucagon secretion is stimulated during hypovolaemia. This facilitates an increase in circulating glucose to raise the plasma osmotic pressure and preserve the blood volume [169]. These effects are instigated by activation of baroreceptors in the carotid sinuses and mediated by the sympathetic nerves, as seen in an experimental study in cats [169]. The signalling mechanisms that contribute to these responses are, however, still to be studied.

Islet autonomic nerves, insulin resistance, diabetes and obesity

It has been shown that there is a close relation between the peripheral insulin sensitivity and insulin secretion because subjects with low insulin sensitivity (insulin resistance) are adapted to secrete more insulin [170, 171]. Experimental induction of insulin resistance in humans by dexamethasone results in the same adaptation [172]. Although the signal mediating this adaptation might involve metabolic factors, such as glucose or non-esterified fatty acids, evidence has accumulated that increased cholinergic activation also participates. Thus, it has been shown that hyperinsulinaemia in the insulin resistant ob/ob mice is considerably reduced by atropine [173] and vagotomy [174] and that in the insulin-resistant state insulin secretion is more readily activated by muscarinic receptor stimulation both in mice [175] and humans [176]. A recent study also showed that cholinergic activation by carbachol returned insulin secretion and glucose intolerance to normal in insulin resistant, high-fat fed mice [177]. Although the relevance of these findings to islet adaptation to insulin resistance is still to be explored in humans, the results suggest that a neural circuit is induced by insulin resistance, the efferent pathway of which, through cholinergic mechanisms, stimulates insulin secretion. A challenging hypothesis is that failure of such a neural circuit results in the development of impaired glucose tolerance or Type II diabetes, conditions mainly characterised by impaired islet adaptation to insulin resistance [171]. An experimental study in a model of Type II diabetes in Chinese hamsters indicated this possibility because islet dysfunction was accompanied by reduced islet innervation [178].

Although hyperinsulinaemia in obesity is mainly a consequence of low insulin sensitivity, it can be speculated that it is a primary event in some cases. It has, for example, been suggested that neurally induced insulin secretion, in particular the cephalic phase regulation of insulin secretion, is exaggerated in pre-obese or obese states, which would result in an inappropriate hyperinsulinaemia after each meal. This in turn would initiate development of obesity, as experimentally verified in rats in which those with the highest cephalic-insulin response to saccharin were found to develop the most obesity when provoked with a fattening diet [119]. Similarly, rats in which the ventromedial hypothalamus has been destroyed secrete more insulin but this increase is reduced by vagotomy in conjunction with the development of obesity [179]. Finally, a study in obese Zucker rats has shown that hyperinsulinaemia evolves before the onset of obesi-
ty [180]. A comparison which was carefully carried out has shown, however, that obese subjects do not have an exaggerated cephalic phase insulin secretion when calculated in per cent of baseline insulin secretion and the net cephalic phase insulin secretion is negatively correlated to body mass index [127]. This does not support a primarily exaggerated cephalic-insulin response in obesity. The increased insulin secretion in the insulin-resistant state in humans (who are, e.g. obese) is therefore probably in most cases secondary to the insulin resistance. Nevertheless, the contribution by a neural (cholinergic) mechanism to this islet adaptation and its consequences for diabetes are still to be studied in more detail.

Conclusions and perspectives

Because of fast and tremendous technological development in several different fields, we now have a fairly well established view of the autonomic innervation of the individual islets, the net effect of activation of the nerves, the presumed neurotransmitters mediating these effects and the putative receptors and their signalling pathways. Still, the following burning issues need to be solved in terms of the physiology and pathophysiology of the islet nerves:

1. The relative contribution the adrenergic, cholinergic and non-adrenergic, non-cholinergic pathways make to the mechanism by which nerves stimulate the islet
2. The role of the individual neurotransmitters, their release and pattern of effect when liberated alone or together with other neurotransmitters
3. The potential involvement of the nerves in islet physiology in conditions other than those related to the cephalic phase and the responses to metabolic stress
4. The possible involvement of the nerves in the pathophysiology of glucose intolerance, Type II diabetes and obesity.

Although suggested by studies undertaken so far, this involvement needs to be more firmly established and the possible mechanisms need to be studied. To this end the development of transgenic animal models and the use of antisense techniques might offer new possibilities for use in combination with more conventional techniques. Therefore, although we have a deeper understanding of the islet nerves than only a few years ago, only fragments of the full picture have emerged.

Acknowledgements. The author is grateful to his collaborators, in particular Drs B. E. Dunning, S. Efendic, P. J. Havel, J. J. Holst, J. W. M. Höppener, S. Karlsson, K. D. Kohner, G. Pacini, A. B. Steffens, J. S. Stern, A. J. W. Scheurink, F. Sund-\n\ner and G. J. Taborský Jr, and to R. Alm, L. Bengtsson, U. Gustavsson, K. Knutsson, L. Kvist and M. Persson for expert technical assistance throughout the years. The studies have been supported by grants to B. Ahrén from the Swedish Medical Research Council (grant no 6834), Swedish Diabetes Association, Novo Nordisk, Albert Pålsson, Ernhold Lundström and Crafoord Foundations, Malmö University Hospital and the Faculty of Medicine, Lund University.

References

73. Nilsson T, Arkhammer P, Rorsman P, Berggren PO (1988) Inhibition of glucose-stimulated insulin release by \( \alpha \)-adrenoceptor activation is paralleled by both a repolarization and a reduction in cytoplasmic free \( Ca^{2+} \) concentration. J Biol Chem 263: 1855–1860
81. Morgan DG, Kulkarni RN, Hurley JD et al. (1998) Inhibition of glucose stimulated insulin secretion by neuropeptide Y is mediated via the Y1 receptor and inhibition of adenylyl cyclase in RIN 5A/6 rat isletoma cells. Diabetesologia 41: 1482–1491
94. Michel MC, Beck Sickinger A, Cox H et al. (1998) Interna-
95. Rosenfeld MG, Mermod JJ, Amara SG et al. (1983) Pro-
96. Karlsson S, Sundler F, Ahrén B (1992) Neonatal capsaicin-treatment in mice: effects on pancreatic peptideergic nerves and 2-deoxy-D-glucose-induced insulin and gluca-
tonin gene-related peptide: occurrence in pancreatic is-
lets in the mouse and the rat and inhibition of insulin se-
cretion in the mouse. Endocrinology 119: 865–869
98. Ahrén B, Märtensson H, Nobin A (1987) Effects of calci-
tonin gene-related peptide (CGRP) on islet hormone se-
cretion in the pig. Diabetologia 30: 354–359
100. Mulder H, Ahrén B, Ekblad E et al. (1999) Islet amyloid polypeptide and adrenomedullin. Novel peptide horm-
in receptor is revealed following co-transfection of a calcitonin receptor with receptor activity modifying pro-
teins-1 or –2. Endocrinology 140: 2924–2927
102. Christopoulos G, Perry KJ, Morfis M et al. (1999) Multi-
ple amylin receptors arise from receptor activity-modify-
ing protein interaction with the calcitonin receptor gene product. Mol Pharmacol 56: 235–242
103. Zunpe ET, Tilarakartne F, Fraser NJ, Christopoulos G, 
ulated insulin secretion in the mouse. Endocrinology 104: 832–838
105. Herman K (1980) Effects of substance P and other peptides on the release of somatostatin, insulin and gluca-
col Rev 43: 143–201
108. Niijima A (1982) Glucose-sensitive afferent nerve fibers in the hepatic branch of the vagus nerve in the guinea-
pig. J Physiol 322: 315–323
109. Guillot E, Costa A, Angel I (1996) Involvement of capsa-
icin-sensitive nerves in the regulation of glucose tolerance in diabetic rats. Life Sci 59: 969–977
tal de-afferentation of capsaicin-sensitive sensory nerves increases in vivo insulin sensitivity in conscious adult rats. Diabetologia 41: 813–820
111. Leighton B, Foot EA, Cooper GJS, King JM (1989) Calci-
tonin gene-related peptide-1 (CGRP-1) is a potent regu-
112. Zhou XF, Jhamadans KH, Livett BG (1990) Capsaicin-
sensitive nerves are required for glucoseostasis but not for catecholamine output during hypoglycemia in rats. Am J Physiol 258:E212–E219
113. Ekblad E, Alm P, Sundler F (1994) Distribution, origin, and projections of nitric oxide synthase-containing neu-
col 280: 27–35
117. Powley T (1977) The ventromedial hypothalamic syn-
drome, satiety, and a cephalic phase hypothesis. Psychol Rev 84: 99–126
118. Berthoud HR, Bereiter DA, Trimble ER, Siegel EG, 
119. Berthoud HR, Bereiter DA, Trimble ER, Siegel EG, 
Jeanrenaud B (1980) Cephalic-phase insulin secretion in 
121. Strubbe JH, Steffens AB (1975) Rapid insulin release af-
123. Berthoud HR, Trimble ER, Siegel EG, Bereiter DA, 
124. Goldfine ID, Abraira C, Gruenwald D, Goldstein MS (1970) Plasma insulin levels during imaginary food inges-
125. Parra-Covarrubias A, Rivera-Rodriguez I, Almarez-Ugal-
Neural regulation of pancreatic hormone secretion by 
neurons in gut and pancreas. Neuroscience 63: 233–248
Cephalic-phase insulin in obese and normal-weight men: relation to postprandial insulin. Metabolism 42: 1600–1608
171. Larsson H, Ahrén B (1996) Failure to adequately adapt reduced insulin sensitivity with increased insulin secretion in women with impaired glucose tolerance. Diabetologia 39: 1099–1107